Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multicenter, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous CT041 Cell Therapy in Patients with Advanced Gastric or Pancreatic Adenocarcinoma

Next Previous
Trial Profile

An Open Label, Multicenter, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous CT041 Cell Therapy in Patients with Advanced Gastric or Pancreatic Adenocarcinoma

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 26 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Satricabtagene autoleucel (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors CARsgen

Most Recent Events

  • 26 May 2020 New trial record
  • 18 May 2020 According to a CARsgen Therapeutics media release, this study will be initiated by CARsgen in Q3 2020 in the United States.
  • 18 May 2020 According to a CARsgen Therapeutics media release, CT041 humanized anti-claudin18.2 autologous Chimeric Antigen Receptor (CAR) T Cells (CT041) has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration (FDA) for the treatment of patients with claudin18.2-positive adenocarcinoma of the stomach, gastroesophageal junction, or pancreas.The IND clearance was supported by an ongoing investigator-initiated Phase I trial (NCT03874897).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top